Dr. David N. Cade, Chief Medical Officer at Telix, noted that the company’s extensive presence at the Vienna event reflects the growing maturity of its pipeline. Twelve of the selected abstracts have been chosen for oral presentations, underscoring the clinical relevance of the data being shared. Key updates include results from the Phase 3 IPAX BrIGHT trial for recurrent glioblastoma and the Phase 3 LUTEON study concerning clear cell renal cell carcinoma (ccRCC).

Beyond pivotal therapeutic studies, the program covers real-world evidence for diagnostic agents and research into targeted alpha therapy. Telix will also host a symposium dedicated to the future of theranostics in urologic oncology. The company plans to facilitate discussions on its broader portfolio, including its medical technology suite, at booth #527 throughout the five-day congress.